The New Standard: From Screening to Prevention

Historically, premarital screening in the UAE focused on communicable diseases and haemoglobinopathies (such as thalassemia and sickle cell disease) . The 2025 mandate represents a significant expansion of this scope, integrating advanced genomic testing to provide a holistic view of a couple's genetic compatibility.

This mandatory test is a proactive measure designed to identify asymptomatic couples who carry mutations in the same genes. It provides crucial information about the risk of transmitting a genetic condition to their children, allowing them to make informed decisions with the support of healthcare professionals and genetic counselors .

Comprehensive Genomic Coverage: 840+ Disorders

The comprehensive genetic testing panel mandated by MoHAP is exceptionally broad, representing one of the most extensive public health screening initiatives globally. The test analyzes over 570 genes linked to more than 840 autosomal recessive and X-linked genetic disorders .

The conditions screened range from common and severe disorders like spinal muscular atrophy (SMA) and cystic fibrosis to a wide array of metabolic, hematologic, and neurological conditions. This includes genes previously listed in DOH addendums covering an extensive array of conditions such as lysosomal storage disorders, hemoglobinopathies (HBA1, HBA2, HBB), and various connective tissue and renal diseases .

Understanding the Risk: Consanguinity and At-Risk Rates

The UAE's investment in this program is partly due to the higher prevalence of recessive genetic disorders in populations with a history of consanguineous marriages (marriages among relatives).

Recent research published in Nature Medicine on a citywide premarital genomic screening program in Dubai found that 8% of couples were identified as 'at-risk,' meaning both partners were carriers of a pathogenic variant in the same gene . This rate is significantly higher than the 1.9-3.9% reported in similar Western studies, highlighting the program's tailored relevance to the UAE's demographic and genetic landscape .

Clinical Workflow: What Couples Can Expect

For Emirati couples, the process is integrated into the existing premarital screening pathway, available at over 22 designated primary healthcare centers across the UAE . The workflow is designed for efficiency and support.

• Sample Collection: A peripheral blood sample is collected from both individuals.
• Laboratory Analysis: The sample undergoes Next-Generation Sequencing (NGS) targeting the mandated genes. The analysis is sophisticated enough to handle genetic complexities, such as the high homology in HBA1/HBA2 genes for alpha-thalassemia, often employing orthogonal methods like long-read sequencing for confirmation .
• Results (14 Days): The results are typically available within 14 days .
• Genetic Counseling: If a couple is identified as 'at-risk' (sharing a pathogenic variant in the same gene), they are mandated to undergo a referral for genetic counseling. A team of specialists explains the risks, probabilities, and available reproductive options to support informed decision-making .

Mandatory Panel vs. Extended Carrier Screening

It is crucial to understand that the government-mandated test, while comprehensive, is a targeted panel focused on severe, actionable recessive conditions. For couples seeking a more in-depth analysis beyond the public health screening—particularly those with a family history of specific cancers, neurological disorders, or other complex diseases—an extended carrier screening panel may be recommended .

Looking Ahead: The Emirates Genome Programme

This mandate is a cornerstone of the broader Emirates Genome Programme, a strategic initiative aimed at building a comprehensive genetic database for the UAE population . By collecting and analyzing genomic data, the program aims to facilitate research, enable the development of personalized medicine, and guide future public health strategies .